Skip to content
Home / Companies / RLAY RLA
Relay Therapeutics, Inc. (RLAY) XNAS BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Net insider selling (90d)
Latest RLAY Insider Trades
About Relay Therapeutics, Inc. (RLAY) Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Headquarters CAMBRIDGE, MA
Employees 192
Listed 2020
Exchange XNAS https://www.relaytx.com SEC filings for RLAY on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 16 6,480,063 $125.05M Grant or award 9 236,741 Option exercise 8 525,804
RLAY Insider Transactions (Form 4) 50 59 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 1 of 2.
Date Insider Transaction Security Shares Price Value Aug 26, 2026 PR Peter Rahmer - Officer Open-market sale Common Stock 4,508
Recent RLAY Form 8-K Filings 5
Recent RLAY Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 26, 2026 PETER RAHMER Officer 50,000 $1.03M View on EDGAR Aug 25, 2026 SVF Pauling (Cayman) Ltd Stockholder
RLAY Insider Trading - FAQ
What is the latest insider trade for RLAY? Relay Therapeutics, Inc. (RLAY) had 20 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for RLAY runs to 59 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying RLAY stock? No insider purchases of RLAY were filed in the last 90 days.
How many insiders are selling RLAY stock? 16 insider sales of RLAY were filed in the last 90 days, totaling $125.05M.
Where can I see RLAY SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks RLAY Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow RLAY insider buys? Create a free InsiderAlpha account and press Watch on this page to add RLAY to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track RLAY insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free $116.40M
Market cap $4.11B
P/E ratio -
Dividend yield -
Average volume 3.33M
52 week high $21.27
52 week low $3.52
Today's high $19.30
Today's low $18.63
Open $19.15
Volume 2.76M
Previous close $19.42
Shares outstanding 219.14M Market cap
$4.11B
192 employees
RLAY Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 16 sales totaling $125.05M.
Most-Active RLAY Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Aug 17, 2026 SP Sanjiv Patel - Officer Open-market sale Common Stock 48,199 $20.33 $980K
Aug 14, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 17,717 $19.74 $350K
Jul 28, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 1,459 $18.61 $27K
Jul 28, 2026 PR Peter Rahmer - Officer Open-market sale Common Stock 748 $18.61 $14K
Jun 30, 2026 SP Sanjiv Patel - Officer Grant or award Common Stock 3,056 $6.95 $21K
Jul 7, 2026 SP Sanjiv Patel - Officer Open-market sale Common Stock 48,199 $19.58 $944K
Jul 6, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 17,717 $18.69 $331K
Jun 30, 2026 PR Peter Rahmer - Officer Grant or award Common Stock 3,056 $6.95 $21K
Jun 30, 2026 PR Peter Rahmer - Officer Open-market sale Common Stock 50,000 $19.09 $955K
Jun 22, 2026 TC Thomas Catinazzo - Officer Option exercise Common Stock 51,560 $4.45 $229K
Jun 22, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 51,560 $16.97 $875K
Jun 22, 2026 TC Thomas Catinazzo - Officer Option exercise Stock Option (Right to Buy) 56,323 $0.00 -
Jun 22, 2026 TC Thomas Catinazzo - Officer Option exercise Stock Option (Right to Buy) 61,563 $0.00 -
Jun 22, 2026 TC Thomas Catinazzo - Officer Option exercise Stock Option (Right to Buy) 51,560 $0.00 -
Jun 22, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 17,717 $17.01 $301K
Jun 22, 2026 TC Thomas Catinazzo - Officer Option exercise Common Stock 56,323 $5.04 $284K
Jun 22, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 56,323 $16.97 $956K
Jun 22, 2026 TC Thomas Catinazzo - Officer Option exercise Common Stock 61,563 $5.22 $321K
Jun 22, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 61,563 $16.97 $1.04M
Jun 22, 2026 DB Donald A. Bergstrom - Officer Option exercise Stock Option (Right to Buy) 93,456 $0.00 -
Jun 9, 2026 CM Claire Mazumdar Grant or award Stock Option (Right to Buy) 32,947 $0.00 -
Jun 9, 2026 HD Habib J. Dable Grant or award Stock Option (Right to Buy) 32,947 $0.00 -
Jun 9, 2026 LH Linda A. Hill Grant or award Stock Option (Right to Buy) 32,947 $0.00 -
Jun 9, 2026 AB Alexis Borisy Grant or award Stock Option (Right to Buy) 32,947 $0.00 -
Jun 9, 2026 MM Mark Murcko Grant or award Stock Option (Right to Buy) 32,947 $0.00 -
Jun 9, 2026 LC Lonnel Coats Grant or award Stock Option (Right to Buy) 32,947 $0.00 -
May 14, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 17,717 $12.86 $228K
Apr 7, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 17,717 $13.01 $230K
Apr 9, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 1,800 $15.00 $27K
Apr 9, 2026 TC Thomas Catinazzo - Officer Option exercise Stock Option (Right to Buy) 1,800 $0.00 -
Mar 9, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 17,717 $10.06 $178K
Dec 31, 2025 PR Peter Rahmer - Officer Grant or award Common Stock 994 $2.99 $3K
Jan 27, 2026 PR Peter Rahmer - Officer Open-market sale Common Stock 11,684 $7.62 $89K
Jan 28, 2026 PR Peter Rahmer - Officer Open-market sale Common Stock 1,354 $8.45 $11K
Jan 27, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 13,820 $7.62 $105K
Jan 28, 2026 TC Thomas Catinazzo - Officer Open-market sale Common Stock 1,695 $8.45 $14K
Jan 13, 2026 DB Donald A. Bergstrom - Officer Grant or award Stock Option (Right to Buy) 575,000 $0.00 -
Jan 13, 2026 PR Peter Rahmer - Officer Grant or award Stock Option (Right to Buy) 475,000 $0.00 -
Jan 13, 2026 SP Sanjiv Patel - Officer Grant or award Stock Option (Right to Buy) 1,450,000 $0.00 -
Jan 13, 2026 TC Thomas Catinazzo - Officer Grant or award Stock Option (Right to Buy) 400,000 $0.00 -
